CDKL5 and craniodiaphyseal dysplasia: In this study, we aimed to address this gap by evaluating the safety and efficacy of Igk-TATk-CDKL5 therapy in a heterozygous female mouse model (Cdkl5 +/−), which better represents the majority of human CDD patients.